2015
DOI: 10.1111/bjh.13597
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: SummaryPlatelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs. Although it is most frequently due to non-immune platelet consumption, immunological factors are also often involved. Human leucocyte antigen (HLA) alloimmunization is the most important immune cause. Despite the fact that systematic reviews of the clinical studies evaluating different techniques for se… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
157
0
11

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 187 publications
(172 citation statements)
references
References 76 publications
(105 reference statements)
4
157
0
11
Order By: Relevance
“…Ann-Kathrin Börger, 1,5* Dorothee Eicke, 1,5* Christina Wolf, 1 Christiane Gras, 1,5 Susanne Aufderbeck, 1 Kai Schulze, 2 Lena Engels, 3,5 Britta Eiz-Vesper, 1 Axel Schambach, 4,5 Carlos A Guzman, 2,5 Nico Lachmann, 4,5 Thomas Moritz, 4,5 Ulrich Martin, 3,5 Rainer Blasczyk, 1,5 and Constança Figueiredo iPSCs were seeded on Laminin-521-coated plates in StemMACS medium. On d 0, the medium was replaced by StemMACS and APEL medium (STEMCELL Technologies; 1:1, vol:vol) containing vascular endothelial growth factor (VEGF; 50 ng/mL) and bone morphogenetic protein 4 (BMP4; 50 ng/mL).…”
Section: Generation Of Hla-universal Ipsc-derived Megakaryocytes and mentioning
confidence: 99%
See 1 more Smart Citation
“…Ann-Kathrin Börger, 1,5* Dorothee Eicke, 1,5* Christina Wolf, 1 Christiane Gras, 1,5 Susanne Aufderbeck, 1 Kai Schulze, 2 Lena Engels, 3,5 Britta Eiz-Vesper, 1 Axel Schambach, 4,5 Carlos A Guzman, 2,5 Nico Lachmann, 4,5 Thomas Moritz, 4,5 Ulrich Martin, 3,5 Rainer Blasczyk, 1,5 and Constança Figueiredo iPSCs were seeded on Laminin-521-coated plates in StemMACS medium. On d 0, the medium was replaced by StemMACS and APEL medium (STEMCELL Technologies; 1:1, vol:vol) containing vascular endothelial growth factor (VEGF; 50 ng/mL) and bone morphogenetic protein 4 (BMP4; 50 ng/mL).…”
Section: Generation Of Hla-universal Ipsc-derived Megakaryocytes and mentioning
confidence: 99%
“…Platelet (PLT) refractoriness represents a relevant clinical concern in transfusion medicine because it is associated with adverse effects including an increased risk of bleeding and reduced survival (1,2). In addition, PLT transfusion refractoriness is associated with significant higher health care costs due to prolonged or repetitive hospital stays (3).…”
Section: Introductionmentioning
confidence: 99%
“…Two recent reviews have detailed practical approaches for the selection of platelet products for patients with alloimmune platelet transfusion refractoriness. 30,31 …”
Section: Genotyping Applications For Hematopoietic Stem Cell and Solimentioning
confidence: 99%
“…After one transfusion, if CCI is less than 5,000/mL, the patient is considered to be refractory. (4,7) Poor response to platelet transfusion may be caused by several immune or non-immune factors related to the patient or to the platelet concentrates. Patient related factors are female gender (related to alloimmunization after pregnancies), splenomegaly, bleeding, infection, disseminated intravascular coagulation, number of transfusion (related to alloimmunization, too), prescribed medication (heparin, amphotericin, antibiotics).…”
Section: Lack Of Response To Platelet Transfusionsmentioning
confidence: 99%